2018
Comparison of Residual Risk–Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies
Wei W, Kurita T, Hess KR, Sanft T, Szekely B, Hatzis C, Pusztai L. Comparison of Residual Risk–Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies. JAMA Oncology 2018, 4: e175092-e175092. PMID: 29372234, PMCID: PMC5885272, DOI: 10.1001/jamaoncol.2017.5092.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantEligibility DeterminationFemaleHumansLymph NodesLymphatic MetastasisMiddle AgedNeoplasm Recurrence, LocalNeoplasm, ResidualPatient SelectionPrognosisRandomized Controlled Trials as TopicReproducibility of ResultsResearch DesignRetrospective StudiesRisk FactorsSurvival AnalysisTrastuzumabTumor BurdenWatchful WaitingYoung AdultConceptsTumor sizeAdjuvant trialsEligibility criteriaNodal statusClinical trialsResidual riskEarly-stage breast cancerAdjuvant clinical trialsBaseline prognostic riskFuture adjuvant trialsResidual risk estimatesRisk of recurrenceBreast cancer therapyRisk thresholdTrial powerClinical trial powerTrial eligibilityAdjuvant therapyCare therapyConsecutive patientsPrognostic riskPatient eligibilityTrial populationPatient cohortControl arm
2011
S1-7: Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome.
Bianchini G, Pusztai L, Iwamoto T, Kelly C, Zambetti M, Fasolo A, Del Conte G, Santarpia L, Symmans W, Gianni L. S1-7: Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome. Cancer Research 2011, 71: s1-7-s1-7. DOI: 10.1158/0008-5472.sabcs11-s1-7.Peer-Reviewed Original ResearchDistant relapse ratesPatterns of relapseAromatase inhibitorsLate relapseRelapse rateHigh riskTime cohortsEstrogen receptor-positive casesOncotype DX recurrence scoreAdjuvant clinical trialsEndocrine-sensitive cancersEndocrine-sensitive tumorsLow-proliferation tumorYears of tamoxifenNode-negative tumorsReceptor-positive casesUse of tamoxifenDX recurrence scoreBiomarker groupsEndocrine therapyEndocrine drugsEarly relapseEndocrine resistanceLate recurrenceRisk stratification